Speech, communication, concentration and behaviour. These are precisely the areas in which parents have been describing changes they observed in their children while taking dimethylglycine (DMG) for decades.
What Do Parents Report?
Interest in DMG is nothing new. The first observations that later attracted the interest of parents and professionals date back to the 1960s.
12 Out of 15 Children – Early Reports from 1965
In 1965, M. G. Blumina and T. K. Belyakova published a paper on the use of a preparation then known as vitamin B15 in children with intellectual disabilities.
According to a later scientific account, 12 out of 15 children showed considerable improvement in speech development after one month. Children who had previously been almost nonverbal expanded their vocabulary, and some began forming simple sentences. Improved concentration and greater interest in toys and games were also reported.
These findings attracted the attention of American psychiatrist Allan Cott, who visited Moscow and subsequently published his own experiences.
In his scientific article from 1975, he also published letters from parents. The mother of four-year-old Jimmy described the changes she had observed in her son in these words:
“It's the most amazing thing I have ever experienced. Before, he would only repeat words; now he answers questions…”
In subsequent letters, she described his expanding vocabulary, a greater desire to communicate and growing interest in interacting with his siblings.
Read Allan Cott's original 1975 article →
31 Out of 39 Children – Observations from Korea
Another interesting historical report comes from the Korean Center for Child Problems, where 39 children with autism who were given dimethylglycine were observed.
According to subsequently published scientific literature, benefits were reported in 80% of the children – approximately 31 out of 39.
The most notable changes described concerned the ability to speak, eating habits, toilet training and a greater willingness to cooperate (“willingness”).
The Korean study was not published independently in a scientific journal, but its findings were subsequently cited by researchers conducting clinical research on DMG.
More Experiences from Parents
Parents' experiences have played an important role in sustaining interest in DMG.
Published experiences repeatedly describe changes in the following areas:
Speech and use of new words • Understanding • Eye contact • Social interaction • Concentration • Managing frustration • Everyday behaviour
Some experiences are particularly specific:
“Definitely worth trying.”
A parent of a child with autism describes how his son took the supplement for 12–18 months and experienced only a few minor behavioural episodes during that period. He also mentions an improved ability to regulate his own behaviour.
“Helps my son with autism.”
Another parent describes a period of significant regression around the age of three, the loss of previously used words, and prolonged daily episodes of crying, screaming and emotional outbursts. In the account, the parent subsequently describes changes observed after introducing DMG.
“I'm ordering it for the fourth time.”
A mother states that she has observed very good results in her child and therefore orders the supplement repeatedly, purchasing several packages at a time.
The statements above represent parents' personal experiences with the use of DMG.
DMG in Clinical Research
Experiences with DMG also led to its investigation in controlled clinical studies.
In 1999, a double-blind, placebo-controlled crossover study was published. During the study, participants received both DMG and placebo and were evaluated using several behavioural assessment scales. The authors highlighted two significant limitations of their research – the small number of participants and the low DMG dosage used.
In 2001, a larger double-blind, placebo-controlled study involving 37 children aged 3 to 11 years followed.
The children were assigned to DMG and placebo groups according to age and gender. The evaluation used standardised behavioural assessment tools, and a neurological examination was also part of the research.
Research continued in subsequent years. In 2022, the scientific journal Current Medicinal Chemistry published an extensive review devoted specifically to N,N-dimethylglycine (DMG) and its research in relation to autism spectrum disorders.
The review summarises existing knowledge about DMG, its properties and clinical research.
DaVinci Laboratories and Decades of DMG Research
American company DaVinci Laboratories has been involved in the research and development of nutritional supplements containing DMG since 1973. More than 20 years of research stand behind its DMG products, and the company has been granted three US patents related to DMG.
Drawing on this experience, Behavior Balance-DMG™ was also developed – a supplement using DMG for the nutritional support of children.
Behavior Balance-DMG™ is available in both liquid and tablet forms, allowing parents to choose the option that best suits their child's age and preferred method of use.
Interested in Trying Behavior Balance-DMG™?
Explore both available formulations, recommended directions for use and further information.
Behavior Balance-DMG™ Liquid →
Behavior Balance-DMG™ Tablets →
Behavior Balance-DMG™ is a food supplement, not a medicinal product.
Sources & Further Reading
Allan Cott (1975)
Pangamic Acid
Original article in the Journal of Orthomolecular Psychiatry →
Bolman & Richmond (1999)
A Double-Blind, Placebo-Controlled, Crossover Pilot Trial of Low Dose Dimethylglycine in Patients with Autistic Disorder
Open publication →
Kern et al. (2001)
Effectiveness of N,N-Dimethylglycine in Autism and Pervasive Developmental Disorder
Open publication →
Dhanjal et al. (2022)
Millennium Nutrient N,N-Dimethylglycine (DMG) and its Effectiveness in Autism Spectrum Disorders
Open scientific review →